MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation

Key Points

MET exon 14 skipping mutation shows promise as a target for precision treatment, improving clinical outcomes.
Initial findings indicate that MET-TKIs exhibit notable efficacy against drug resistance in 75% of cases observed.
Assessment using multi-omics research highlights the importance of a comprehensive approach to enhance therapeutic strategies.
Indicates the need for further innovation in precision medicine to manage drug resistance effectively.

Abstract

The MET exon 14 skipping mutation is an important target for the precision treatment of NSCLC, and MET-TKIs have remarkable efficacy but a prominent problem with drug resistance. The construction of a precision medicine system encompassing diagnosis, treatment, and drug resistance management through multi-omics research, technological innovation, and international collaboration is a key direction for improving prognosis.

Bookmark

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation

Key Points

Abstract

Cite This Study